News & Press
Synchron completes $75M Series D ahead of anticipated pivotal trial for FDA clearance
Bloomberg Health3/29/2026·03/29/26🌐 USA
Summary
Synchron closed a $75M Series D led by ARCH Venture Partners, with participation from Gates Frontier, Bezos Expeditions, and Apple co-founder Steve Wozniak. The funding will support a planned pivotal trial to support FDA De Novo application for the Stentrode BCI as an assistive communication device for severe motor impairment.
Why it matters
Wozniak and Bezos joining the investor base signals growing tech industry conviction in Synchron's endovascular approach. The De Novo pathway is appropriate for a first-of-kind device and suggests Synchron is confident in their safety profile.
#ALS#BCI#FDA#Industry#Neural Interfaces#Pivotal Trial#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in